v3.25.1
Net Loss Per Share - Schedule of Diluted Loss Per Share Anti-Dilutive (Details) - shares
 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Schedule of Diluted Loss per Share Anti-Dilutive [Line Items]            
Anti-dilutive shares 11,798,977 11,500,680 11,643,768 11,500,226 11,521,080 4,272,062
Convertible preferred stock [Member]            
Schedule of Diluted Loss per Share Anti-Dilutive [Line Items]            
Anti-dilutive shares    
Preferred stock warrants [Member]            
Schedule of Diluted Loss per Share Anti-Dilutive [Line Items]            
Anti-dilutive shares 1,037,177
Stock options [Member]            
Schedule of Diluted Loss per Share Anti-Dilutive [Line Items]            
Anti-dilutive shares [1] 11 1 11 1    
SSCPN [Member]            
Schedule of Diluted Loss per Share Anti-Dilutive [Line Items]            
Anti-dilutive shares 15,307
Public warrants [Member]            
Schedule of Diluted Loss per Share Anti-Dilutive [Line Items]            
Anti-dilutive shares 11,500,000 11,500,000 11,500,000 11,500,000 11,500,000
Private warrants [Member]            
Schedule of Diluted Loss per Share Anti-Dilutive [Line Items]            
Anti-dilutive shares 19,416 [1] 644 [1] 19,416 [1] 214 [1] 19,416
Unsecured convertible note [Member]            
Schedule of Diluted Loss per Share Anti-Dilutive [Line Items]            
Anti-dilutive shares 35 12 1,653
Warrants issued along with redeemable promissory note [Member]            
Schedule of Diluted Loss per Share Anti-Dilutive [Line Items]            
Anti-dilutive shares 75,000 55,909    
Warrants issued in November 2024 and December 2024 offering [Member]            
Schedule of Diluted Loss per Share Anti-Dilutive [Line Items]            
Anti-dilutive shares 204,551 68,432    
[1] The computation of diluted earnings per common share excludes the 11 common stock options (204 prior to Second Reverse Stock Split and 20,425 prior to First Reverse Stock Split) for the three months and nine months ended December 31, 2024 respectively and 1 common stock option (7 prior to Second Reverse Stock Split and 674 prior to First Reverse Stock Split) for the three months and 1 common stock option (2 prior to Second Reverse Stock Split and 224 prior to First Reverse Stock Split) for the nine months ended December 31, 2023 respectively and the 19,416 private warrants (380,011 prior to Second Reverse Stock Split and 37,956,206 prior to First Reverse Stock Split) for the three months and nine months ended December 31, 2024 respectively and 35 private warrants (12,876 prior to Second Reverse Stock Split and 1,287,616 prior to First Reverse Stock Split) for the three months and 12 private warrants (4,276 prior to Second Reverse Stock Split and 427,639 prior to First Reverse Stock Split) for nine months ended December 31, 2023 respectively.